Physician profile
Adam Repole
NPI 1619902046
$2,911.62
in general payments reported to CMS, 2019-2025
26 companies · $666 in 2025
The $666 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $418 · 2020: $90.16 · 2021: $309 · 2022: $461 · 2023: $592 · 2024: $375 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,527 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,526.53 |
| Education | $107.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $558.50 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $376.29 | 2019-2023 | |
| Hologic Sales and Service, LLC | $283.79 | 2019-2024 | Myosure Tissue Removal Device, Fluent Fluid Management System, Acessa Provu System |
| Sumitomo Pharma America, INC. | $206.70 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $203.56 | 2019-2025 | |
| Pfizer INC. | $198.13 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $133.09 | 2022-2025 | |
| Millicent US INC | $99.77 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Daiichi Sankyo INC. | $90.51 | 2021-2024 | Injectafer |
| Exact Sciences Corporation | $87.11 | 2023-2025 | Cologuard Collection Kit |
| Evofem Biosciences, INC. | $80.24 | 2021-2025 | Phexxi, Solosec, Phexx |
| Myriad Women'S Health, INC. | $80.22 | 2023 | Myrisk |
| Organon LLC | $76.10 | 2022-2025 | Nexplanon |
| Myovant Sciences INC. | $75.34 | 2021-2022 | |
| Therapeuticsmd, INC. | $59.37 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $57.28 | 2019-2023 | Slynd |
| Coopersurgical, INC. | $53.08 | 2019-2025 | Paragard T 380a |
| Radius Health, INC. | $42.19 | 2022-2023 | |
| Amgen INC. | $29.94 | 2019-2023 | Evenity, Prolia |
| Agile Therapeutics, INC. | $26.31 | 2021-2022 | |
| Medtronic, INC. | $19.64 | 2021 | |
| Smith+Nephew, INC. | $18.31 | 2024 | Pico 7 |
| Allergan, INC. | $14.93 | 2019 | |
| Shield Therapeutics INC | $14.43 | 2025 | |
| Merck Sharp & Dohme LLC | $13.40 | 2020 | |
| Amag Pharmaceuticals, INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Repole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.